Published in Vox Sang on January 01, 1994
Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet (1990) 4.99
Sexual transmission of hepatitis C virus. Lancet (1993) 4.27
Hepatitis C virus six years on. Lancet (1994) 4.09
Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet (1991) 3.97
Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutinin. Biochim Biophys Acta (1970) 3.31
Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet (1993) 3.20
White blood cell fragments in platelet concentrates prepared by the platelet-rich plasma or buffy-coat methods. Vox Sang (2005) 2.77
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang (2005) 2.47
Prevention of Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet (1992) 2.44
The effect of storage time of human red cells on intestinal microcirculatory oxygenation in a rat isovolemic exchange model. Crit Care Med (2005) 2.26
Oxygen consumption of phagocytizing cells in human leukocyte and granulocyte preparations: a comparative study. J Lab Clin Med (1974) 2.14
Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med (1996) 2.05
Evaluation of six enzyme immunoassays for antibody against human immunodeficiency virus. Lancet (1986) 2.04
Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin. Lancet (1979) 2.03
Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. II. Relative importance of glycolysis and oxidative phosphorylation on phytohaemagglutinin stimulation. Exp Cell Res (1973) 1.87
In vivo labelling of intermediates in the discontinuous synthesis of mRNAs in Trypanosoma brucei. EMBO J (1987) 1.87
Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed) (1983) 1.86
Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet (1989) 1.82
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis (2005) 1.80
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissue. J Virol Methods (1994) 1.62
Protection of phagocytic leukocytes by endogenous glutathione: studies in a family with glutathione reductase deficiency. Blood (1979) 1.60
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis (2006) 1.56
Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. J Clin Microbiol (1992) 1.49
Monitoring of platelet morphology during storage of platelet concentrates. Transfusion (1989) 1.47
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43
Cord blood banking. Vox Sang (2008) 1.41
International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods (1996) 1.41
Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang (2001) 1.39
[The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]. Ned Tijdschr Geneeskd (2005) 1.39
Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol (1999) 1.37
Donors with a rare pheno (geno) type. Vox Sang (2008) 1.35
Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol (1992) 1.33
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat (2015) 1.22
Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang (2003) 1.22
Blood donations reactive for HIV in Western blot, but non-infective in culture and recipients of blood. Lancet (1986) 1.18
Bacterial contamination in platelet concentrates. Vox Sang (2014) 1.18
Evaluation of a new haemagglutination technique for the demonstration of hepatitis-B antigen. Lancet (1973) 1.18
Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet (1983) 1.17
Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang (2011) 1.16
Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in The Netherlands. Vox Sang (1991) 1.15
Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion (1995) 1.15
Ficoll-isopaque gradients for the determination of density distributions of human blood lymphocytes and other reticulo-endothelial cells. Exp Cell Res (1974) 1.14
Amplified-fragment length polymorphism analysis of Propionibacterium isolates implicated in contamination of blood products. Br J Haematol (2005) 1.13
The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion (2001) 1.11
Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion (1993) 1.09
Early antihepatitis C virus response with second-generation C200/C22 ELISA. Vox Sang (1992) 1.08
Large-scale purification and cryopreservation of human monocytes. J Immunol Methods (1981) 1.08
Earlier detection of HIV and second-generation antibody assays. Lancet (1987) 1.05
Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet (1989) 1.04
Stability of hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification. J Virol Methods (1998) 1.03
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat (2015) 1.02
Prolonged storage of red blood cells affects aminophospholipid translocase activity. Vox Sang (2006) 1.00
Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells. Biochim Biophys Acta (1989) 1.00
Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion (1990) 0.98
Deferral of males who had sex with other males. Vox Sang (2011) 0.98
Neonatal transfusions. Vox Sang (2009) 0.97
Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. Vox Sang (1992) 0.96
Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat Res (1994) 0.96
Evaluation of a simple method for determination of IgG titre anti-A or-B in cases of possible ABO blood group incompatibility. Vox Sang (1972) 0.96
Blast cell leukaemia associated with IgA paraproteinaemia and Bence Jones protein. Br J Haematol (1970) 0.95
Comparison between a new PVC platelet storage container (UPX80) and a polyolefin container. Transfus Med (2000) 0.93
In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system. Vox Sang (2009) 0.92
Mother-to-infant transmission and hepatitis C virus. Lancet (1990) 0.92
Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Anal Biochem (1985) 0.91
Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang (2004) 0.91
Donor selection: the exclusion of high risk donors? Vox Sang (1998) 0.91
Bacterial contamination of blood components. Vox Sang (2000) 0.90
Prevention and diagnosis of delayed haemolytic transfusion reactions. Vox Sang (2006) 0.90
Genotyping for red blood cell polymorphisms. Vox Sang (2009) 0.90
Look-back study of infectivity of anti-HCV ELISA-positive blood components. Lancet (1995) 0.90
Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. Vox Sang (1995) 0.90
Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial. J Med Virol (1994) 0.90
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. J Viral Hepat (2015) 0.89
Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool-screening systems. Transfusion (2000) 0.89
Management of alloimmune thrombocytopenia. Vox Sang (2007) 0.89
Efficacy of selected versus random blood donor screening for anti-HTLV-I antibodies. Vox Sang (1995) 0.89
Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. J Gastroenterol (2001) 0.89
Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost (1996) 0.88
Clinical importance of HIV antigen and anti-HIV core markers in persons infected with HIV. N Engl J Med (1988) 0.88
Detection of bacterial contamination of platelet concentrates. Vox Sang (2007) 0.88
Interpretation of isolated HIV anti-p24 reactivity in Western blot analysis. Lancet (1987) 0.88
Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther (2011) 0.88
Chronic hepatitis E after solid organ transplantation. Neth J Med (2012) 0.88
Bacterial screening of platelet concentrates: results of 2 years active surveillance of transfused positive cultured units released as negative to date. Vox Sang (2009) 0.88
Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med (1985) 0.88
Transfusion-transmissible infections. Curr Opin Hematol (1998) 0.87
Evidence for transformation-related increase in CTP synthetase activity in situ in human lymphoblastic leukemia. Eur J Biochem (1993) 0.87
Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients. Scand J Gastroenterol (1992) 0.87
Prevalence of and risk factors for HIV infection in blood donors and various population subgroups in Ethiopia. Epidemiol Infect (2002) 0.86